Posted by Michael Wonder on 22 Dec 2018
Multiple sclerosis drug Mavenclad to be heavily subsidised in the new year under PBS
22 December 2018 - A multiple sclerosis drug will be heavily subsidised in the new year, saving sufferers $54,000 a year.
Hundreds of South Australians living with the most common form of multiple sclerosis could save $54,000 a year when a new drug becomes subsidised next month.
The drug Mavenclad, used to treat people with relapsing remitting multiple sclerosis, will be listed on Pharmaceutical Benefits Scheme from January 1.
